Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

NEXT STORY
Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
PREV STORY
Trillium Closes US$150 Million Public Offering of Common Shares
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) to Reduce the Risk of Major Adverse Cardiovascular Events Based on Landmark REDUCE-IT™ Cardiovascular Outcomes Study

author_avatar
NASDAQ Market News

Sharps Compliance Reports Fiscal 2018 Fourth Quarter and Year End Results

Fourth quarter 2018 revenue was $9.9 million with gross margin of 30% and net ...

author_avatar
NASDAQ Market News

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio

author_avatar
NASDAQ Market News